Myriad Genetics Outlines Strategy for Driving Long-Term Value From MDx Pipeline | GenomeWeb

NEW YORK (GenomeWeb) – Although Myriad Genetics' forecasted revenues for fiscal year 2017 fell short of Wall Street's expectations, the company yesterday outlined its plan for diversifying its product portfolio and achieving long-term growth.

The company reported FY2016 revenues of $753.8 million, a 4 percent increase from the prior year, and said it is expecting revenues of between $740 million to $760 million in FY2017. Analysts were expecting $755.5 million in revenues for FY2016 and had modeled $788.9 million for the coming 12 months. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

Dec
06
Sponsored by
Natera

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.